Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody in patients with pancreatic cancer
Pancreatic Cancer
RADIATION: Radiation|DRUG: Anti-PD-1 Antibody
Local control, occurrence of local or regional progression, 2 year
Incidence of Treatment-Emergent Adverse Events, Number of participants with treatment-related adverse events as assessed by Number of participants with treatment-related adverse events as assessed by treatment-related adverse events assessed by CTCAE v4.0, 3 months|Objective response rate, Objective response rate as assessed by RECIST criteria, 3 months|Overall survival, Overall survival, 2 year
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody in patients with pancreatic cancer